Latest Biotechnology, Pharmaceutical and Healthcare News from PharmaTimes

12:57 EDT 21st March 2018 | BioPortfolio

Here are the most relevant search results for "PharmaTimes" found in our extensive news archives from over 250 global news sources.

More Information about PharmaTimes on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PharmaTimes for you to read. Along with our medical data and news we also list PharmaTimes Clinical Trials, which are updated daily. BioPortfolio also has a large database of PharmaTimes Companies for you to search.

Showing News Articles 1–25 of 977 from PharmaTimes

Wednesday 21st March 2018

Ines Mastrolia joins Cognite

US expands scope of Seattle Genetics’ Adcetris

US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.

Novartis links with NHS Cancer Vanguard sites

Swiss drug giant Novartis has announced the launch of two new joint working projects with national Cancer Vanguard sites, which aim to determine novel ways of boosting patient care pathways and access to services.

Charity forms Alzheimer’s disease taskforce

Alzheimer’s Research UK is calling on the NHS and the pharma industry to join its new taskforce to ensure people with dementia can access future treatments without unnecessary delay.

Skin conditions cost NHS £723m a year

New research shows that more than three million primary care hours are spent on skin conditions, at a cost to the NHS of £723 million each year.

NIHR launches new standards for public involvement in research

The National Institute for Health Research (NIHR) has launched a new set of national standards for public involvement in clinical research for use by organisations across the UK.

Tuesday 20th March 2018

Søren Tulstrup appointed new President and CEO of Hansa Medical

NICE rejects rare eye disease drug

Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.

Real world data back Sanofi’s Toujeo for type I diabetes

Sanofi has unveiled real-world data from the UK showing the efficacy of its long-acting basal insulin analogue Toujeo in treating patients in type I diabetes.

Napp secures distribution rights to Celltrion’s Herzuma

Napp Pharmaceuticals has secured itself exclusive UK distribution rights to Celltrion Healthcare’s Herceptin biosimilar Herzuma.

MPs call on government to help with Orkambi debate

MPs are calling on the NHS England and Vertex to come to an agreement over the price of cystic fibrosis drug Orkambi.

Monday 19th March 2018

Performance on A&E target slips further

NHS hospital performance against the four-hour A&E target stood at just 74.96 percent, well under the 95 percent target, for the week ending March 11th, show the most recent data from the Royal College of Emergency Medicine’s Winter Flow Project.

Coeliac UK launches new research fund and appeal

Coeliac UK has launched a new research fund and fundraising appeal that aims to raise £5 million to improve understanding and management of coeliac disease and gluten related autoimmune conditions.

Lundbeck snaps up Parkinson’s candidate via Prexton buy

Lundbeck has announced plans to buy Prexton Therapeutics in a deal valued at up to 905 million euros.

US nod for CSL Behring’s Hizentra

US regulators have cleared CSL Behring’s Hizentra for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder affecting the peripheral nerves that can cause permanent nerve damage.

Friday 16th March 2018

PharmaTimes Clinical Researcher of the Year – The Americas: Book now!

Clinical researchers in the Americas have submitted their essays for this year's competition and yesterday, the authors and finalists were revealed at a meeting of the executive steering group.

Number of prescriptions rises as net ingredient cost falls

The number of medicines prescribed on the NHS in England increased in 2017 but their net ingredient cost took a downturn, according to data released by NHS Digital.

International Clinical Researcher of the Year 2108 – Venue announced

PharmaTimes Clinical Researcher of the Year – one of the most important dates in the clinical research calendar - will take place on 17 May at the Millennium Gloucester Hotel in the heart of London’s Kensington.

Amryt in-licenses novel gene therapy platform from UCD

UK biotech Amryt has secured itself access to a novel gene therapy platform that could give rise to a new treatment option for patients with Epidermolysis bullosa (EB), a group of rare inherited skin disorders that cause the skin to become very fragile.

Alexion gears up to file new blood disorder drug

Alexion is gearing up to file its experimental therapy for paroxysmal nocturnal hemoglobinuria (PNH) with regulators on both sides of the Altantic following the success of a late-stage clinical trial.

NICE endorses Keytruda for bladder cancer

MSD’s Keytruda is the first and only immunotherapy to be recommended for NHS use to treat urothelial carcinoma patients, when prior platinum-containing chemotherapy fails.

Thursday 15th March 2018

Researchers call for investigation into rising mortality rates

Researchers are calling for a government investigation into the “substantial increase” in mortality seen in early 2018 in England and Wales.

New guidelines recommend hysteroscopy test for heavy periods

More women in England and Wales are to be offered a test to better determine the causes of heavy menstrual bleeding, on updated guidelines from the National Institute for Health and Care Excellence.

Patients on diabetes scheme shed weight of 15 double cheeseburgers

According to NHS England more than half of patients routinely attending sessions offered as part of its diabetes prevention programme have achieved weight losss equivalent to nearly 15 double cheeseburgers.

Charities link with BenevolentAI to discover new AMD therapies

BenevolentAI has teamed up with Action Against AMD* to find treatments and a potential cure for age-related macular degeneration, the leading cause of blindness in the UK.

Quick Search


News Quicklinks